Current and Potential Inflammation Targeted Therapies in Head and Neck Cancer

Overview

Journal Curr Opin Pharmacol

Specialty Pharmacology

Date 2009 Jul 3

PMID 19570715

Citations 48

Authors

Frederick Wang

Pattatheyil Arun

Jay Friedman

Zhong Chen

Carter Van Waes

Affiliations

Soon will be listed here.

Abstract

Inflammation often exists in the tumor microenvironment and is induced by inflammatory mediators (cytokines, chemokines, and growth factors) produced by the tumor, stroma, and infiltrating cells. These factors modulate tissue remodeling and angiogenesis and actively promote tumor cell survival and chemoresistance through autocrine and paracrine mechanisms. Head and neck squamous cell carcinomas (HNSCCs) are highly inflammatory and aggressive in nature, and they express a number of cytokines and growth factors involved in inflammation. These cytokines and growth factors activate important signal transduction pathways, including NF-kappaB, JAK/STAT, and PI3K/Akt/mTOR, which regulate the expression of genes controlling growth, survival, and chemosensitivity. This review provides an update on recent advances in the understanding of the mechanisms driving cancer-related inflammation in HNSCC and on molecular targeted therapies under preclinical and clinical investigation.

Citing Articles

Intra-tumoral bacteria in head and neck cancer: holistic integrative insight.

Meng Y, Deng J, Deng W, Sun Z Cancer Biol Med. 2025; 22(2).

PMID: 39969204 PMC: 11899592. DOI: 10.20892/j.issn.2095-3941.2024.0311.

Analysis of Th1/Th2 cytokine profile and clinical characteristics of patients with head and neck squamous cell carcinoma.

Wang R, Yin G, Guo W, Li N, Zhang Y, Chen X Biomol Biomed. 2024; 24(6):1776-1784.

PMID: 38920620 PMC: 11496867. DOI: 10.17305/bb.2024.10783.

Exploring the Link between Inflammatory Biomarkers and Head and Neck Cancer: Understanding the Impact of Smoking as a Cancer-Predisposing Factor.

Nuszkiewicz J, Wroblewska J, Budek M, Czuczejko J, Wozniak A, Maruszak-Parda M Biomedicines. 2024; 12(4).

PMID: 38672104 PMC: 11048483. DOI: 10.3390/biomedicines12040748.

Bolnykh I, Patterson J, Harding S, Watson L, Lu L, Hurley K J Cancer Surviv. 2024; .

PMID: 38421499 DOI: 10.1007/s11764-024-01554-x.

Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects.

Khadela A, Shah Y, Mistry P, Bodiwala K, Cb A Technol Cancer Res Treat. 2023; 22:15330338221150559.

PMID: 36683526 PMC: 9893386. DOI: 10.1177/15330338221150559.

References

Loeffler-Ragg J, Schwentner I, Sprinzl G, Zwierzina H . EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2008; 17(10):1517-31. DOI: 10.1517/13543784.17.10.1517. View

Zhang Q, Eaton L, Snyder E, Houghtaling S, Mitchell J, Finegold M . Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res. 2008; 68(5):1601-8. DOI: 10.1158/0008-5472.CAN-07-5186. View

Friedman J, Nottingham L, Duggal P, Pernas F, Yan B, Yang X . Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res. 2007; 13(22 Pt 1):6568-78. DOI: 10.1158/1078-0432.CCR-07-1591. View

Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C . Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res. 2008; 14(13):4175-85. DOI: 10.1158/1078-0432.CCR-07-4470. View

Gurova K, Hill J, Guo C, Prokvolit A, Burdelya L, Samoylova E . Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A. 2005; 102(48):17448-53. PMC: 1297696. DOI: 10.1073/pnas.0508888102. View

Lee T, Yeh J, Van Waes C, Chen Z . Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther. 2006; 5(1):8-19. DOI: 10.1158/1535-7163.MCT-05-0069. View

Lin D, Subbaramaiah K, Shah J, Dannenberg A, Boyle J . Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002; 24(8):792-9. DOI: 10.1002/hed.10108. View

Kanazawa T, Nishino H, Hasegawa M, Ohta Y, Iino Y, Ichimura K . Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol. 2007; 264(7):815-21. DOI: 10.1007/s00405-007-0264-6. View

Sharma R, Euden S, Platton S, Cooke D, Shafayat A, Hewitt H . Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10(20):6847-54. DOI: 10.1158/1078-0432.CCR-04-0744. View

10.

Nishimoto N, Kishimoto T . Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006; 2(11):619-26. DOI: 10.1038/ncprheum0338. View

11.

Anand P, Sundaram C, Jhurani S, Kunnumakkara A, Aggarwal B . Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008; 267(1):133-64. DOI: 10.1016/j.canlet.2008.03.025. View

12.

Van Waes C, Yu M, Nottingham L, Karin M . Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res. 2007; 13(17):4956-9. DOI: 10.1158/1078-0432.CCR-07-1287. View

13.

Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C . Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2007; 6(1):37-50. DOI: 10.1158/1535-7163.MCT-05-0285. View

14.

Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E . Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008; 44(12):1093-9. DOI: 10.1016/j.oraloncology.2008.02.012. View

15.

Messaoudi S, Peyrat J, Brion J, Alami M . Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008; 8(7):761-82. DOI: 10.2174/187152008785914824. View

16.

Czerninski R, Amornphimoltham P, Patel V, Molinolo A, Gutkind J . Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila). 2009; 2(1):27-36. DOI: 10.1158/1940-6207.CAPR-08-0147. View

17.

Camacho M, Leon X, Fernandez-Figueras M, Quer M, Vila L . Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck. 2008; 30(9):1175-81. DOI: 10.1002/hed.20850. View

18.

King K, Ponnamperuma R, Allen C, Lu H, Duggal P, Chen Z . The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res. 2008; 68(13):5122-31. PMC: 2692507. DOI: 10.1158/0008-5472.CAN-07-6123. View

19.

Dhillon N, Aggarwal B, Newman R, Wolff R, Kunnumakkara A, Abbruzzese J . Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008; 14(14):4491-9. DOI: 10.1158/1078-0432.CCR-08-0024. View

20.

Molinolo A, Amornphimoltham P, Squarize C, Castilho R, Patel V, Gutkind J . Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2008; 45(4-5):324-34. PMC: 2743485. DOI: 10.1016/j.oraloncology.2008.07.011. View